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 Disorders of intracellular cobalamin metabolism in-
clude methylmalonic acidaemia and homocystinuria. 
These inborn errors of metabolism can manifest with 
dysmorphism, developmental delay, encephalopathy 
and megaloblastic anaemia. Cobalamin F (cblF) is a co-
factor in the vitamin B12 metabolism pathway, encoded 
by the  LMBRD1 gene on chromosome 6q13 [Rutsch et 
al., 2009]. Deficiency is inherited in an autosomal reces-
sive fashion, characteristically associated with intrauter-
ine growth restriction, failure to thrive, congenital heart 
disease, developmental delay, macrocytic anaemia, neu-
tropaenia, thrombocytopaenia, hyperhomocysteinaemia 
and methylmalonic aciduria [Alfadhel et al., 2011]. It is 
usually diagnosed through urine organic acid and plas-
ma amino acid analysis. Molecular analysis of  LMBRD1 
can be used to confirm the genetic basis of the disease. 
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 Abstract 
 Cobalamin F (cblF) disorder, caused by homozygous or com-
pound heterozygous mutations in the  LMBRD1 gene, is a rec-
ognised cause of developmental delay, pancytopaenia and 
failure to thrive which may present in the neonatal period. A 
handful of cases have been reported in the medical litera-
ture. We report a new case, diagnosed at the age of 6 years 
through whole exome sequencing, with atypical features in-
cluding prominent metopic suture, cleft palate, unilateral re-
nal agenesis and liver abnormalities, which broaden the 
phenotypic spectrum.  © 2015 The Author(s)
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 Established Facts 
 • Cobalamin F disorder is caused by homozygous or compound heterozygous mutation in  LMBRD1. 
 • Typical presenting features include poor growth, developmental delay and macrocytic anaemia with 
neutropaenia and thrombocytopaenia. 
 Novel Insights 
• Cleft palate, renal agenesis, prominent metopic suture and neonatal liver dysfunction may be features 
of the disorder.
 • Whole exome sequencing is a non-invasive route to diagnosis in rare developmental disorders where 
neonatal clinical and biochemical findings are inconclusive. 
This article is licensed under the Creative Commons Attribution 4.0 
International License (CC BY) (http://www.karger.com/Services/
OpenAccessLicense). Usage, derivative works and distribution are 
permitted provided that proper credit is given to the author and the 
original publisher.
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We present a 6-year-old child with an atypical presenta-
tion of cblF disorder, diagnosed by whole exome se-
quencing (WES).
 Case Report 
 The proband was referred to our genetic service at the age of 
1 month due to cleft palate, thrombocytopaenia and renal agenesis. 
The pregnancy history was notable for pregnancy-associated hy-
pertension, for which the mother was managed with methyldopa. 
Prenatal ultrasonography demonstrated limb shortening and de-
creased liquor volumes. Delivery was by emergency lower segment 
Caesarian section at 32 weeks’ gestation for fetal distress. APGAR 
scores were 8 at 1 min and 9 at 5 min after delivery. Growth pa-
rameters at birth were: weight 1,100 g (1.4th centile for gestational 
age), length 34 cm (<0.4th centile), and head circumference 28 cm 
(8th centile). Physical examination revealed a prominent metopic 
ridge, midline cleft soft palate, low-set ears, broad nasal tip, micro-
gnathia and undescended testes with a right-sided inguinal hernia 
( fig. 1 ). Ophthalmological assessment revealed abnormal retinal 
streaking pigmentation. Imaging demonstrated thoraco-lumbar 
scoliosis and right renal agenesis. A small patent ductus arteriosus 
with mild peripheral pulmonary artery stenosis was identified, 
which resolved spontaneously by the age of 3 years. He had feeding 
difficulties and required parenteral nutrition during the first 6–8 
weeks of life. Thrombocytopaenia and neutropaenia were evident, 
initially attributed to sepsis and treated with antibiotics. A bone 
marrow examination was normal apart from neutrophil matura-
tion arrest at the metamyelocyte stage, which responded to granu-
locyte colony stimulating factor. He also had persistent conjugated 
hyperbilirubinaemia. A liver biopsy at 3 months of age revealed a 
paucity of bile ducts, but molecular analysis of  JAG1 for suspected 
Alagille syndrome was normal. Biochemical investigation at 
6 weeks of age revealed a non-specific aminoaciduria with a slight-
ly increased plasma homocysteine, in addition to peaks of methyl-
malonic acid, p-hydroxyphenyllactic acid and p-hydroxyphenyl-
pyruvic acid on organic acid analysis. These findings were attrib-
uted to hepatic insult and inadequate vitamin supplementation 
while on parenteral nutrition. A single dose of intramuscular hy-
droxocobalamin was given and folate supplementation was insti-
tuted by tube feeding, continuing until the age of 3 years. Repeat 
biochemical studies at 2 and 3 months of age demonstrated an 
improvement in the biochemical profile ( table 1 ). At this time, care 
was transferred to another team and permanent enteral feeding 
was commenced by percutaneous gastrostomy. As the initial blood 
abnormalities appeared to have resolved, further diagnostic inves-
tigation was not pursued at this stage.
 Severe global developmental delay was apparent on follow-up. 
Unaided sitting was first recorded at around 3 years of age, and 
walking, with a wide-based gait, was first recorded at around 
6 years of age. A mild intention tremor was noted from the age of 
4 years. There was no speech on the last review at age 10, but he 
also had bilateral sensorineural deafness and communicated using 
some simple Makaton signing. He had proportional short stature 
with a height of 116 cm (<0.4th centile), weight 23.8 kg (5th cen-
tile), and a head circumference of 49 cm (<0.4th centile).
 Array comparative genomic hybridisation analysis (Nimblegen 
CGX array v1.0) was normal as was a standard karyotype. At 6 years 
of age, he was entered into the Deciphering Developmental Disor-
ders Study and WES was performed [methods described in the 
 Deciphering Developmental Disorders Study, 2015]. This dem-
onstrated a homozygous pathogenic mutation c.1056delG; 
p.Leu352fs * 18 in the  LMBRD1 gene, which was subsequently con-
firmed by Sanger sequencing. Heterozygosity for this mutation was 
confirmed in both parents. No other potentially pathogenic vari-
ants were detected in any known development gene, no regional 
homozygosity was detected in the exome data using BCFtools v1.0, 
and no evidence of isodisomy was seen. After establishing the mo-
lecular diagnosis, biochemical studies were performed, revealing 
modestly elevated plasma homocystine and urine methylmalonic 
acid levels. Regular intramuscular hydroxocobalamin supplemen-
tation was instituted at this time, resulting in normalisation of the 
a b c
 Fig. 1. Frontal view of the facial characteristics.  a Shortly after birth.  b At age 3 years.  c At age 6 years. 
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biochemical findings ( table 1 ). There has been no change in his de-
velopmental status in the 2 years since starting therapy although 
growth parameters have improved slightly ( fig. 2 ). 
 Discussion 
 We present a new case of cblF disorder, presenting in 
an atypical manner with a prominent metopic suture, 
cleft palate, unilateral renal agenesis, feeding difficulties, 
and early liver abnormalities, which was diagnosed late by 
the use of WES. To date, a total of 15 cases have been re-
ported in the literature [Rosenblatt et al., 1986; Shih et al., 
1989; MacDonald et al., 1992; Wong et al., 1992; Wag-
goner et al., 1998; Rutsch et al., 2009; Gailus et al., 2010; 
Miousse et al., 2011; Oladipo et al., 2011] in addition to a 
recent case of combined cblF/cblG disorder suggestive of 
digenic inheritance [Farwell Gonzalez et al., 2015]. The 
typical clinical phenotype of cblF disorder is failure to 
Table 1.  Biochemical findings in the proband
Age Plasma  Urine Comments
MMA
(<10 μmol/mmol 
creatinine)
cysteine 
(20 – 80 μM)
methionine
(10 – 60 μM)
homocystine 
(0 – 1 μM)
homocysteine
(0 – 20 μM)
B12
(200 – 700 ng/l)
 MMA
(<10 μmol/mmol 
creatinine)
homocystine
(<1 μmol/mmol 
creatinine)
6 w    29  530  modestly elevated plas-
ma phenylalanine and 
tyrosine
2 mo    11 170 >1,000 304 96 after supplementation
3 mo    4 107 55 31  
7.75 ys   28 <1 33 202 30 5 at molecular diagnosis
8.1 ys 4 39 29 2 11 >2,000 16 after instituting 
hydroxocobalamin
8.5 ys 12 40 34 <1 13  13  
8.75 ys 5 34 34 1 13  12  
9 ys <1 45 20 <1 14 <1 2  
9.5 ys  40 19 <1 17     
9.8 ys <1 42 29 1 14  12  
 MMA = Methylmalonic acidaemia; mo = months; w = weeks; ys = years. Values in bold print represent abnormal results..
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 Fig. 2. Growth parameters in the proband 
before and after institution of intramuscu-
lar (IM) hydroxocobalamin. 
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thrive and feeding difficulties, developmental delay and 
haematological features including megaloblastic anae-
mia, neutropaenia and thrombocytopaenia ( table 2 ). All 
but one of the previously described cases carry the 
c.1056delG; p.Leu352fs * 18. Of the 7 cases that are homo-
zygous for this mutation, the majority displayed develop-
mental delay, haematological findings and failure to 
thrive, though their phenotypes were otherwise variable. 
Hepatic involvement and prominent metopic suture or 
dysmorphism as found in our patient have been infre-
quently described [Oladipo et al., 2011, Rutsch et al., 
2009]. Cleft palate has not been described previously in 
cblF deficiency, but has been reported with other disor-
ders of vitamin B12 and folic acid metabolism [Natsume 
et al., 1998; Weingärtner et al., 2007; Boyles et al., 2008]. 
Renal tubulointerstitial dysfunction has been described 
in disorders of cobalamin metabolism [Morath et al., 
2013] as has reduced renal growth [Kruszka et al., 2013]. 
Renal agenesis has, however, not been described.
 Early institution of intramuscular hydroxocobalamin 
corrects the biochemical abnormalities of hyperhomocys-
teinaemia and methylmalonic acidaemia and appears to 
limit the severity of cognitive and neurological impair-
ment [Alfadhel et al., 2011]. Although late institution of 
intramuscular hydroxocobalamin corrected the biochem-
ical profile in our patient, there has unfortunately been no 
effect on the severity of the patient’s developmental delay, 
though there appears to be a trend of improvement in 
growth paramaters. The initial biochemical abnormalities 
might have guided towards the diagnosis, but were instead 
attributed to the effects of parenteral nutrition as they were 
partly corrected with modification of the regimen. In ret-
rospect, the resolution of the haematological abnormali-
ties also coincided with the institution of enteral nutrition 
and vitamin supplementation, but did not recur when vi-
tamin supplementation was subsequently reduced. By vir-
tue of his continued gastrostomy feeding, some vitamin 
supplementation has continued throughout his child-
hood, and this may explain why the usual haematological 
and biochemical features have not re-appeared. It should 
be noted that both prematurity and parenteral nutrition 
are associated with hepatic biochemical abnormalities 
[Schutzman et al., 2008]. We cannot be certain how much 
the cblF disorder contributed to the hepatic dysfunction in 
this case. This study supports the utility of a genomic test-
ing approach to make an early diagnosis for neonates with 
a complex clinical presentation, as has been previously 
suggested elsewhere [Saunders et al., 2012].
 The first 1,133 family trios from the Deciphering De-
velopmental Disorders Study have now been reported, 
with an overall diagnostic yield of 27% [Deciphering De-
velopmental Disorders Study, 2014; Wright et al., 2015]. 
One of the outcomes from the initial analysis has been the 
broadening of the phenotypic spectrum of previously 
well-described monogenic developmental disorders. The 
importance of high-quality or deep clinical phenotyping 
of rare diseases in the genomic era cannot be underesti-
mated. It will improve our understanding of the natural 
history of these disorders, and may reveal findings that 
will affect clinical management. As in this case, it may re-
veal new genotype-phenotype correlations, giving a bet-
ter understanding of the molecular bases of developmen-
tal disorders and hopefully facilitating the development 
of targeted therapies.
 In summary, this new case of cblF deficiency, diag-
nosed via WES, broadens the phenotypic spectrum of the 
condition. It is likely that the incorporation of WES into 
clinical practice will highlight wider phenotypic variabil-
ity in previously defined disorders.
Table 2.  Clinical features of cblF disorder described in the litera-
ture compared to features seen in our patient
Features Number of 
affected 
patients
Our patient
Developmental delay 7 +
Failure to thrive 7 +
Haematological features 6 +
Congenital cardiac anomalies 6 +
Small for gestational age 6 +
Stomatitis +/– glossitis 5
Gastric upset 3
Dental anomalies 3
Feeding difficulties 3 +
Microcephaly 2 +
Seizures 2
Hypotonia 2
Torticollis 1
Pes equinovarus 1
Tracheoesophageal fistula 1
Intrauterine growth retardation 1 +
Arthritis 1
Hepatic involvement 1 +
Rash 1
Recurrent infection 1
Facial dysmorphism 1 +
Recurrent apnoea 1
Encephalopathy 1
Cleft palate 0 +
Unilateral renal agenesis 0 +
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